(BMRN) |
| 0 (0%) 05-29 22:44 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 67.16 |
| Resistance 1: | 57.50 |
| Pivot price: | 52.75 |
| Support 1: | 52.41 |
| Support 2: | 49.26 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 1.390 |
| Book Value | 32.140 |
| PEG Ratio | 0.46 |
| Gross Profit | 8.589 |
| Profit Margin (%) | 8.29 |
| Operating Margin (%) | 18.00 |
| Return on Assets (ttm) | 4.5 |
| Return on Equity (ttm) | 4.5 |
Company news
Fri, 29 May 2026
5 Stocks That Could 10X by 2030 - Insider Monkey
Wed, 27 May 2026
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - simplywall.st
Mon, 25 May 2026
Why BioMarin (BMRN) Is Up 8.9% After VOXZOGO’s Phase 3 Success In Hypochondroplasia Trial - simplywall.st
Sun, 24 May 2026
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $111 - Moomoo
Sat, 23 May 2026
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Thu, 21 May 2026
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid - Fierce Pharma
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
